PhaseBio Pharmaceuticals — FY2018 Earnings Presentation
27 slides from PhaseBio Pharmaceuticals's earnings presentation, Mar 26, 2019
Slide 1: Q4 and Full Year 2018 Financial Results
Q4 and Full Year 2018 Financial Results March 26, 2019 Exhibit 99.3
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”)
Slide 3: Company Overview
Company Overview Therapeutic Focus Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications Product Candidates PB2452 – Novel agent for immediate and sustained reversal of ticag
Slide 4: A Clinical Stage, Orphan Disease-Focused Biopharmaceutical Company
Program Indication/Therapeutic Area Pre-Clinical Phase 1 Phase 2 Phase 3 WW Commercial Rights Milestones PB2452 Reversal of Ticagrelor Antiplatelet Activity 1H 2019: Initiate Phase 2a Report Phase 2a results 2H 2019: Initiate Phase 2b 2020: Initiate Phase 3 based on plan to pursue accelerated regula
Slide 5: Corporate
Corporate
Slide 6: Recent Corporate Highlights
Recent Corporate Highlights Reported PB2452 Phase 1 results Presented as a late breaking oral presentation at the American College of Cardiology Scientific Sessions on March 17, 2019 Simultaneously published in the New England Journal of Medicine Secured up to $15 million term loan facility from Sil
Slide 7: Full-Year 2018 Financial Highlights
Full-Year 2018 Financial Highlights Operating expense: $20.3M R&D: $15.5M SG&A: $4.9M Loss from Operations: ($19.6M) Net Loss of ($23.8M) or ($4.49) per share 5.3M shares used for computing FY 2018 net loss per share Cash and cash equivalents as of 12/31/2018: $61.0M Shares outstanding as of 03/15/2
Slide 8: PB2452 – Reversal Agent for Ticagrelor
PB2452 – Reversal Agent for Ticagrelor
Slide 9: PB2452 - Novel reversal agent for Brilinta (ticagrelor)
PB2452 - Novel reversal agent for Brilinta (ticagrelor) Human monoclonal antibody fragment (Fab), delivered intravenously in the hospital Phase 1 Proof of Concept Study completed Selected for late-breaking oral presentation at 68th Annual American College of Cardiology Scientific Sessions (March 17,
Slide 10: PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor
PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor ADP ADP Platelet ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation This is a reversible process with ticagrelor cycling on/off the P2Y12 receptors PB2452:ticag
Slide 11: PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects
PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects Selected as late-breaking oral presentation during featured clinical research session at the 68th Annual Scientific Session of the American College of Cardiology – March 17, 2019 Simultaneously published in the New England Journal of Medicine
Slide 12: PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects
PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects Randomized, double-blind, placebo-controlled, single ascending dose (SAD), sequential group study (n=64) 3:1 randomization, PB2452-Placebo Higher-dose cohorts pre-treated with ticagrelor After 48 hours of ticagrelor, platelet aggregation was
Slide 13: Platform Function After Ticagrelor Reversal - LTA
Platelet Function After Ticagrelor Reversal - LTA Normalization of platelet response to ADP was assessed by whether reversal of ticagrelor achieved a normal range of platelet function Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med
Slide 14: PB2452 Clinical Development Plan Based on FDA Accelerated Approval Pathway
PB2452 Clinical Development Plan Based on FDA Accelerated Approval Pathway Regulatory Strategy based on Pre-IND discussion of Accelerated Approval Phase 2a study to confirm dosing in an older, healthy-for-age population Large Phase 2b study will develop safety database Phase 3 non-randomized trial c
Slide 15: Continued Long Term Unit Growth of Ticagrelor Fueled by PB2452 approval
Continued Long Term Unit Growth of Ticagrelor Fueled by PB2452 approval Brilinta/Brilique sales in 2018 were $1.32B and growing (+22% Y/Y) Patient growth drives Y/Y revenue growth in all regions: EU (+18%), US (+16%), Emerging Markets (+46%) In February 2019, Brilinta Phase III THEMIS1 trial met pri
Slide 16: PB2452 Program Summary and Next Steps
PB2452 Program Summary and Next Steps Phase 1 trial achieved clinically-important immediate and sustained reversal of ticagrelor Well tolerated and no PB2452-related SAEs Product profile: Immediate and sustained reversal of ticagrelor antiplatelet effects Major bleeding requires immediate and sustai
Slide 17: Elastin-Like Polypeptide Technology (ELP) – Engine for Growth
Elastin-Like Polypeptide Technology (ELP) – Engine for Growth
Slide 18: Prolonged Circulating Half-Life
PROLONGED CIRCULATING HALF-LIFE Repeating Sequence of Human Elastin Peptides VPGXG Peptide/Protein (VIP, GLP1, etc.) Active Moiety “Biopolymer” n UP TO 200x INCREASE IN ½ LIFE Proprietary Elastin-Like Polypeptide (ELP) Technology Growth Engine for PhaseBio Preclinical Pipeline ↑ Temperature COACERVA
Slide 19: ELP: A Highly Flexible Technology for Modulating Pharmacokinetics
ELP: A Highly Flexible Technology for Modulating Pharmacokinetics VERSATILE: MANY ACTIVE MOIETIES POSSIBLE Peptides or proteins can be genetically fused to N- or C-terminus1, or both. Chemical conjugation to small molecules or peptides LOW COST MANUFACTURING Can be produced in E.coli, yeast or mamma
Slide 20: PB1046 - Once Weekly VIP Analog for Pulmonary Arterial Hypertension
PB1046 - Once Weekly Vasoactive Intestinal Peptide (VIP) Analog for Pulmonary Arterial Hypertension
Slide 21: High Unmet Need in an Orphan Disease
High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) High unmet need for novel disease-modifying PAH therapies for greater efficacy All 3 approved drug classes in PAH are vasodilators: prostacyclin, endothelin, and nitric oxide pathways Patients inevitab
Slide 22: PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug
PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug PRECLINICAL STUDIES Support Clinical Development for: Pulmonary Arterial Hypertension DMD Cardiomyopathy Heart Failure (Chemotherapy-Induced HF or HFpEF) Cystic Fibrosis MECHANISM OF ACTION VIA VPAC2 RECEPTOR Potent vasodilator Anti-inflamm
Slide 23: Phase 1 Studies Completed
PHASE 1 Studies Completed PAH PHASE 2 Studies Well tolerated for a week over broad range of exposure; no drug-related SAEs Prolonged PK/PD profile over 1 week VIP activity confirmed (Systolic and Diastolic BP lowering) Well tolerated across dose range; no drug-related SAEs Replicated PK/PD from SAD
Slide 24: PB1046 Single Ascending Dose Study
PB1046 Single Ascending Dose Study PK and PD Support Once-Weekly SC Administration Single subcutaneous injections in hypertensive patients washed off medications Well tolerated, week-long PK, dose-dependent VIP activity observed Supports weekly SC dosing in multi-dose studies Serum Concentration PB1
Slide 25: PB1046 Multiple Ascending Dose Study
PB1046 Multiple Ascending Dose Study Multi-Dose Safety and PK/PD Confirmed in HFrEF Patients MAD in HFrEF completed 4Q2017 Weekly SC injections x 4 weeks in 29 HF patients maintained on SOC meds Well tolerated in a sick patient population on multiple vasoactive medications Prolonged PK profile repli
Slide 26: PB1046 Phase 2b PAH Study Actively Recruiting
PB1046 Phase 2b PAH Study Actively Recruiting PAH WHO functional class II/III subjects on two drug oral SOC therapy 16 week randomized, double-blinded, controlled study with extension Primary endpoints: Pulmonary vascular resistance (PVR) via RHC, 6MWD, safety Designed to support placebo-controlled
Slide 27: Slide 27
PhaseBio Pharmaceuticals — FY2018 Earnings Presentation on 6ix